TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01266824
Drug: Proparacaine Hydrochloride Ophthalmic Solution
Normalized name: Proparacaine Hydrochloride Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop into each eye once prior to the first set of mydriatic (dilating) eye drops
Study: NCT00411450
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy consisting of irinotecan with infusional 5-fluorouracil and leucovorin. Recommended dosage regimen and administration of FOLFIRI was based on local standard of care, the package insert for each product, and institutional guidelines.
Study: NCT04069221
Drug: iv infusion of [14C]-OZ439
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-minute 10-mL iv infusion of 100 μg \[14C\]-OZ439
Study: NCT01589367
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 2.5mg PO daily + Placebo 1 tablet PO 2/day x 1week Letrozole 2.5mg PO daily + Placebo 2 tablet+ 1 tablet PO x 1 week Letrozole 2.5mg PO daily + Placebo 2 tablet PO 2/day x 22 weeks
Study: NCT01852318
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01882543
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double blind placebo capsule
Study: NCT03854721
Drug: VAX014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for intravesical infusion, 3.33x10\^10 rBMCs per vial
Study: NCT01793038
Drug: Aromatase inhibitor (litrezole) plus uFSH arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: literozole tablets 5 mg /day for days 3-7 plus intramuscular injections of uFSH 37.5 IU/day for days 3-12
Study: NCT02849743
Drug: Placebo (for Syntocinon)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo is identical to the Syntocinon formulation with the exception of the active compound, i.e., without oxytocin.
Study: NCT01759706
Drug: Epidural analgesia with naropin + sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midthoracic epidural analgesia with naropin 0.2 % plus sufentanil 0,5 mcg/mL
Study: NCT03175081
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient undergo elective laparoscopic sleeve gastrectomy will receive 200mL normal saline to be injected through a catheter along the greater curvature and left subdiaphragmatic region of the stomach at the end of the surgical procedure. After the surgery, the medical doctors or nurses in the ward that is not otherwise involved in this research will assess and record the pain score using visual analog scale (VAS) (0-10). The abdomen and shoulder tip pain intensity will be rated at two, four, six, eight, 24 and 48 hours postoperatively.
Study: NCT04518618
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Spinal anesthesia will be performed with injection of 2.5 ml which will be composed of 10 mg hyperbaric bupivacaine (2 ml) and 25 ugs fentanyl (0.5 ml)
Study: NCT04164121
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration was conducted on an empty stomach, and the drug was administered once a day on day 1 and once a day from day 8 to day 17.
Study: NCT01372358
Drug: CIPRO®XR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 1000 mg Tablets Dr. Reddy's Laboratories Limited
Study: NCT00650494
Drug: Valtrex® 1000 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mg, single dose fed
Study: NCT01980680
Drug: Progesterone and Estradiol
Normalized name: medroxyprogesterone and estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01610037
Drug: QVA149
Approvals — FDA: no, EMA: no, PMDA: no
Description: QVA149 110/50 µg will be supplied as capsules in blister packs for once daily inhalation using the Novartis Concept1 SDDPI
Study: NCT00462644
Drug: RSI sedation with etomidate/succinylcholine
Approvals — FDA: no, EMA: no, PMDA: no
Description: etomidate 0.3 mg/kg IV plus succinylcholine 1 mg/kg IV
Study: NCT00462644
Drug: RSI sedation with fentanyl/midazolam/succinylcholine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 micrograms fentanyl IV, plus 5 mg midazolam IV, plus 1 mg/kg succinylcholine IV
Study: NCT01610037
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo to QVA149A and Tiotropium will be supplied in the appropriate capsule in blister packs for use in either the Novartis Concept1 SDDPI or the HandiHaler SDDPI
Study: NCT00107887
Drug: INH preventive therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinics will receive training regarding the use of IPT for prevention of Tuberculosis
Study: NCT00107887
Drug: TST (tuberculin skin test)
Normalized name: TST, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinics will be trained in the use of TST for assessing exposure to TB
Study: NCT04572828
Drug: 550 mg Naproxen Sodium 60 minutes before the procedure
Normalized name: naproxen sodium 550 MG
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 550 mg Naproxen Sodium (Abdi Ibrahim, Turkey) will be given to participants in the Group 4, 60 minutes before the procedure.
Study: NCT02788721
Drug: GLPG2451 single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG2451 oral suspension, single ascending doses, daily
Study: NCT02788721
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, oral suspension, daily
Study: NCT03124160
Drug: Mona Lisa® NT Cu380 Mini
Approvals — FDA: no, EMA: no, PMDA: no
Description: copper intrauterine device
Study: NCT03124160
Drug: ParaGard® TCu380A
Approvals — FDA: no, EMA: no, PMDA: no
Description: copper intrauterine device
Study: NCT04458805
Drug: NX-13 250 mg
Normalized name: Replesta NX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation in Part A will be conducted in a total of 5 cohorts (Cohorts 1 to 5). Seven participants will be enrolled in each cohort and will be randomized to receive either NX-13 or placebo (ratio 5:2). NX-13 will be administered to Cohort 1 participants at the starting dose of 250 mg. The NX-13 dose will be increased in each new cohort. Five nominal dose levels in the range of 250 to 4000 mg have been selected for evaluation in Part A.~It is anticipated that 3 dose levels will be evaluated in Part B in a total of 3 cohorts (Cohorts 6 to 8). Seven participants will be enrolled in each cohort and will be randomized to receive a single oral dose of either NX-13 or placebo (ratio 5:2), once daily for seven days.
Study: NCT04458805
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation in Part A will be conducted in a total of 5 cohorts (Cohorts 1 to 5). Seven participants will be enrolled in each cohort and will be randomized to receive either NX-13 or placebo (ratio 5:2). NX-13 will be administered to Cohort 1 participants at the starting dose of 250 mg. The NX-13 dose will be increased in each new cohort. Five nominal dose levels in the range of 250 to 4000 mg have been selected for evaluation in Part A.~It is anticipated that 3 dose levels will be evaluated in Part B in a total of 3 cohorts (Cohorts 6 to 8). Seven participants will be enrolled in each cohort and will be randomized to receive a single oral dose of either NX-13 or placebo (ratio 5:2), once daily for seven days.
Study: NCT00953888
Drug: AZD5069
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of oral solution.
Study: NCT00953888
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of oral solution.
Study: NCT01287793
Drug: tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous, 200 mg, single dose
Study: NCT01287793
Drug: tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous, 50 mg, single dose
Study: NCT01287793
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% Sodium Chloride intravenous 100mL, single dose
Study: NCT04157686
Drug: MT10109L Dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: MT10109L Dose 2 will be injected into the LCL area
Study: NCT00324974
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole placebo-matching suspension, orally, once daily for up to 28 days.
Study: NCT04157686
Drug: MT10109L Dose 1 + Dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: MT10109L Dose 1 will be injected into the GL area plus MT10109L Dose 2 will be injected into the LCL area
Study: NCT00371189
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline.
Study: NCT03619447
Drug: serratus block group
Normalized name: Fucus serratus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: USG guided serratus plane block will perform bilaterally
Study: NCT03489343
Drug: Sym023
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sym023 is a recombinant, fully human antibody that binds TIM-3 and induces activation of immune cells.
Study: NCT02517957
Drug: Mullite ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applies to a blister, pustule, erosion, ulcer, leaking or comorbid folliculitis, in skin lesions of 2 times a day, 5 days for one period of treatment, but for two consecutive period of treatment
Study: NCT00402792
Drug: Hydrocodone/Acetaminophen Extended-Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet q 12 hours
Study: NCT00402792
Drug: Hydrocodone/Acetaminophen Extended Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets q 12 hours
Study: NCT00402792
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets q 12 hours
Study: NCT00128102
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorinostat-matching placebo oral capsules
Study: NCT01945346
Drug: PRX167700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT01945346
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT00201344
Drug: Cisplatin,5-FU,Leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02435303
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04131283
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vasoconstrictor solution is applied on the surface of the attached gingiva and on the gingival sulcus.
Study: NCT01581177
Drug: Placebo DPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo DPI with 0 mcg Albuterol/inhalation
Study: NCT02897050
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1200mg/m2/d, po, d1-d21
Study: NCT02897050
Drug: Cyclophosphamide (tablet)
Normalized name: cyclophosphamide Oral Tablet
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 50 mg/d, po, d1-d21
Study: NCT02897050
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil 500mg/m2, iv, d1
Study: NCT02897050
Drug: Cyclophosphamide (injection)
Normalized name: cyclophosphamide Injection
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 500mg/m2, iv, d1
Study: NCT01396889
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.5ml daily for children 1-2 years old and 2ml daily for children 2-5 years old) for 3 months
Study: NCT00362245
Drug: Systemic and Intra-Thecal Amikacin Therapy
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02541864
Drug: Hybrid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: (pantoprazole 40 mg bid for 7 days, amoxicillin 1 g bid for 7 days) followed by (pantoprazole 40 mg bid for 7 days, amoxicillin 1 g bid for 7 days, clarithromycin 500 mg bid for 7 days, and metronidazole 500 mg bid for 7 days)
Study: NCT01526564
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 t.i.d, two plates per time
Study: NCT01531673
Drug: Placebo matched to VX-661
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02084563
Drug: Induction Chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy for patients with AML eligible for intensive chemotherapy:~* Cytarabine 200 mg/m2 IV continuous infusion days 1-7~* Daunorubicin 90 mg/m2 intravenous piggyback days 1-3
Study: NCT02084563
Drug: Consolidation Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consolidation chemotherapy for patients eligible for intensive chemotherapy with low-risk AML or patients with intermediate-/high-risk AML who do not have matched donors:~-Cytarabine 1.5 g/m2 IV in 3 hours days 1, 3 and 5 for 3 cycles
Study: NCT04196491
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lymphodepleting Chemotherapy
Study: NCT02389452
Drug: Synvisc-One
Normalized name: Synvisc-One 48mg/6ml Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: intraarticular injection
Study: NCT00954265
Drug: 250 mcg recombinant HCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ovulation triggering
Study: NCT03790852
Drug: KSI-301
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection
Study: NCT05264493
Drug: NaxRedy ™
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg (5 mg/0.5 mL) IM autoinjector injection into lateral thigh
Study: NCT00414908
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00727935
Drug: Ropivacaïne
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00727935
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00564590
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4 mg of Melatonin once a day for 3 months
Study: NCT00564590
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once a day
Study: NCT02522975
Drug: EPIAO®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant human erythropoietin falls under the pharmacological class of haematopoietic / anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease.~Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000.
Study: NCT02522975
Drug: EPREX®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant human erythropoietin falls under the pharmacological class of haematopoietic /anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease.~Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000.
Study: NCT03742986
Drug: Doxorubicin 60mg/m^2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 60 mg/m\^2 IV on Day 1 of every 14 day cycle (Cycle 5-8)
Study: NCT03742986
Drug: Cyclophosphamide 600mg/m^2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 600mg/m\^2 on Day 1 of every 14 day cycle (Cycle 5-8)
Study: NCT02385617
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline (1mL) single dose, subcutaneously, into the lower abdomen, 50 minutes prior to eating
Study: NCT04565756
Drug: EXN407
Approvals — FDA: no, EMA: no, PMDA: no
Description: EXN407 or placebo will be administered as a single 30 microliters drop twice a day, by unilateral eye drop administration to the study eye only.
Study: NCT03066830
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT03066830
Drug: Sulfonylurea
Normalized name: Sulfonylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT03799679
Drug: Chemotherapeutic Agent
Normalized name: Other chemotherapeutics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Nanoparticle Albumin-Bound Paclitaxel Nanoparticle Albumin-Bound Paclitaxel 125mg/m2, iv, d1. Patients will receive this as a single-agent for the first twelve weeks, then followed by epirubicin in combination with cyclophosphamide.~Drug: Epirubicin 90 mg/m² given IV~Drug: Cyclophosphamide 600 mg/m² given IV
Study: NCT04425993
Drug: Indomethacin 100 MG
Normalized name: indomethacin 100 MG
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients without contraindications should receive rectal indomethacin within 30 min before ERCP.
Study: NCT04425993
Drug: Sublingual Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients without contraindications should receive sublingual placebo within 5 minutes before ERCP.
Study: NCT04425993
Drug: Rectal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients without contraindications should receive rectal placebo within 30 min before ERCP.
Study: NCT00152113
Drug: See intervention description
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea and azathioprine were administered for a 3 month period prior to the initiation of the transplant procedure in an effort to help prevent rejection of the donor product. Approximately 10 days prior to the transplant procedure, all participants received the same preparative regimen consisting of Busulfan, cyclophosphamide, low-dose thiotepa, and OKT3. MMF was administered for GVHD prophylaxis. Two separate infusions of donor stem cells were administered with fixed doses of CD3 and CD34 cells. These haploidentical stem cells were processed using the investigational CliniMACS device.
Study: NCT02635282
Drug: intranasal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02881177
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 IU
Study: NCT04420689
Drug: ALM-488
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALM-488 Sterile Solution is an intravenously administered, synthetic, peptide dye conjugate indicated for the real-time intraoperative fluorescence detection and localization of nerve tissue.
Study: NCT00753675
Drug: Placebo matching ZD6474
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match ZD6474 100 mg as a once daily oral dose, from Day 1 until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
Study: NCT02141191
Drug: inhaled hypertonic saline (7%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled hypertonic saline delivered by nasal cannula using the Parion transnasal Pulmonary Aerosol Delivery (tPAD) device
Study: NCT01720316
Drug: Glycine
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Double-blind placebo controlled trial of glycine or placebo, followed by open-label glycine
Study: NCT01720316
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00713271
Drug: AZD3199
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose~Dry powder for inhalation, o.d., 1+12 days
Study: NCT00713271
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00713271
Drug: AZD3199
Approvals — FDA: no, EMA: no, PMDA: no
Description: intermediate dose~Dry powder for inhalation, o.d., 1+12 days
Study: NCT00713271
Drug: AZD3199
Approvals — FDA: no, EMA: no, PMDA: no
Description: high dose~Dry powder for inhalation, o.d., 1+12 days
Study: NCT03568578
Drug: Anluohuaxian Pill 12g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this group will be given Entecavir 0.5 mg and Anluohuaxian Pill 12g a day for 2 years
Study: NCT03669601
Drug: AZD6738
Approvals — FDA: no, EMA: no, PMDA: no
Description: A potent, selective inhibitor of the serine/threonine-specific protein kinase, ataxia telangiectasia and Rad3-related protein (ATR), with good selectivity against other phosphatidylinositol 3-kinase-related kinase (PIKK) family members.
Study: NCT00080353
Drug: rF-go 100P209
Normalized name: Go-dry
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00036283
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00369343
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, daily (QD), tablet form, treatment period up to 8 weeks
Study: NCT04001803
Drug: CAB LA+RPV LA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive one tablet of CAB 30 milligram(mg) + RPV 25 mg once daily from Day 1 for 1 month. During month 1, subjects will receive 600 mg of CAB LA injection+ 900 mg of RPV LA injection. Following Month 1, subjects will receive 400mg of CAB LA + 600mg of RPV LA at each subsequent injection.
Study: NCT04014218
Drug: Inhalation Sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation Sedation by Administration of Sevoflurane
Study: NCT04014218
Drug: Intravenous Sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Sedation by Administration of Propofol
Study: NCT00461825
Drug: Group A: CsA + Azathioprine(1 to 2 mg/kg/day)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00461825
Drug: Group B: CsA + CellCept(500 mg x 2/day)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00461825
Drug: Group C: CsAm
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02021214
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02539017
Drug: Chemo
Normalized name: Chemolock
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin,75mg/m2,intravenous ,on day 1 of each 21 day cycle, 4 cycles Cyclophosphamide,0.6g/m2,intravenous, on day 1 of each 21 day cycle, 4 cycles Docetaxel,75mg/m2, intravenous, on day 1 of each 21 day cycle, 4 cycles
Study: NCT03159832
Drug: SHR3824
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects were given SHR3824 20mg only one time.
Study: NCT01945944
Drug: Hypertonic saline (3%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3mL of HTS given via nebulizer every 6hrs
Study: NCT00526318
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00526318
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01776970
Drug: Cannabis Sativa extract Oromucosal spray
Normalized name: Cannabis sativa whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between active drug (Cannabis Sativa extract Oromucosal spray, containing THC (27 mg/ml):CBD (25 mg/ml) vs placebo
Study: NCT03573037
Drug: Oral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1:1 randomization to 1-month anticoagulation or 2-month anticoagulation after radiofrequency catheter ablation of paroxismal atrial fibrillation